Answers are grounded in this paper and cite their sources.
The implementation of the Model for End-Stage Liver Disease (MELD) scoring system in February 2002 ushered in a new era in liver transplantation in the United States. MELD was developed to estimate mortality of patients awaiting liver transplantation, and the use of this scoring system for the allocation of livers was in response to a government mandate to distribute organs based on medical necessity. A key component of the MELD score is renal function. Therefore, many clinicians anticipated that more patients with renal dysfunction would receive liver transplants. How this will have an impact on overall results and patient survival following liver transplantation remains to be determined, but one paper has already suggested that posttransplantation survival is correlated with pretransplantation MELD score.1 Although some centers have demonstrated good results regardless of pretransplantation renal function (excepting those requiring renal replacement therapy [RRT]), impaired pretransplantation renal function is generally accepted as a poor prognostic indicator of survival following liver transplantation.2-6 Previous analysis of the United Network for Organ Sharing (UNOS) database had indicated that patients with serum creatinine greater than 2.0 mg/dL or those requiring RRT had worse outcomes when compared to patients undergoing transplantation with serum creatinine less than 2 mg/dL. Single center studies had verified the poor outcome in those who required either pre- or postoperative RRT.7-9 The same analysis of the UNOS database had demonstrated that patients receiving combined liver kidney transplant has a superior outcome to patients with a creatinine > 2 mg/dL who received a liver transplant alone. However, patients having hepatorenal syndrome (HRS) were found to recover renal function with a low incidence of end-stage renal disease (ESRD) following transplantation.7, 9, 10 It has therefore been recommended that patients without fixed renal disease and those with HRS only receive a liver transplant and not the combined procedure.9, 11 This was generally accepted, and the number of combined transplantations done per year in the United States remained relatively stable until 2002 (Figs. 1, 2). As can be seen, combined liver kidney transplantation has dramatically increased in both absolute number and as a percentage of the total coincident with the introduction of the MELD system. What can account for this rise, and what implications does it have for the future? Combined liver kidney transplantations in the United States 1994-2004. The data are based on the Organ Procurement and Transplantation Network (OPTN) data as of March 11, 2005. Data subject to change due to future data submission or correction. Combined liver kidney transplantations in the United States 1994-2004 as a percentage of total liver transplantations. The data are based on the Organ Procurement and Transplantation Network (OPTN) data as of March 11, 2005. Data subject to change due to future data submission or correction. MELD, Model for End-Stage Liver Disease; RRT, renal replacement therapy; UNOS, United Network for Organ Sharing; HRS, hepatorenal syndrome; ESRD, end-stage renal disease. Previously reported analysis of UNOS data and data from an individual center had demonstrated that patients undergoing liver transplantation alone who either had a creatinine greater than 2.0 mg/dL or were undergoing RRT at the time of transplantation had a decreased 1-year patient survival compared with patients receiving a combined liver kidney transplant (See Jeyarajah et al.,7, 11 Gonwa et al,8 and Maureen McBride, personal communication, UNOS data for the period 1994-1998). One-year patient survival was reported to be 62% in patients with a creatinine > 2.0 mg/dL, 68% in patients undergoing RRT at the time of transplantation and 78% for patients undergoing combined liver kidney transplantation. Although single center data demonstrated no difference in 1-year survival in patients with HRS receiving liver alone, patients with creatinine greater than 2 mg/dL, patients on RRT at the time of transplantation, or patients undergoing combined transplantation, many clinicians may be persuaded to proceed with combined transplantation under those circumstances based on the national data. Furthermore, the growing awareness of nephrotoxicity associated with long-term use of immunosuppressive agents leading to chronic kidney disease and ESRD in liver transplant recipients12-14 has led many centers to consider combined transplantation as a way to avoid long-term problems. The introduction of the MELD system has not changed this perception and, in fact, may have strengthened it. The number of patients receiving a liver transplant alone with creatinine > 2.0 mg/dL or who were receiving RRT at the time of transplantation has increased (Maureen McBride, personal communication, UNOS). From 1999 to 2001, 4.3% of patients receiving a liver transplant alone received RRT prior to transplantation, and 12.3% had serum creatinine > 2.0 mg/dL. By comparison, in 2002 to 2003, 4.8% of patients received RRT prior to transplantation, and 14.1% had serum creatinine > 2.0 mg/dL. If you consider that from 1999 to 2001 2.4% of patients received a liver kidney transplant, and from 2002 to 2003 4% received a combination, then the totals for patients receiving a liver transplant with renal dysfunction from 1999 to 2001 was 19%, compared with 22.9% from 2002 to 2003. The effect of this rise in patients with renal dysfunction on overall patient survival has not been rigorously studied. Unfortunately, this has significant implications for the patients awaiting kidney transplantation. As of the end of 2004, there were 60,531 patients awaiting kidney transplantation in the United States. During the period July 2003 to July 2004, 4,311 patients died while on the kidney transplant waiting list, compared with 2,395 who died while on the liver waiting list. The median waiting time in the United States for kidneys now exceeds 4 years. Table 1 lists the probability of surviving on dialysis by age group from the latest United States Renal Data System reports (http://www.usrds.org). Studies have shown that one of the largest modifiable factors affecting post–kidney transplantation patient survival is time on dialysis.15 Thus, every kidney used for a combined liver kidney transplant may have a profound effect on a patient waiting for a kidney transplant. How, then, can a clinician decide in whom to perform a combined transplantation? The paper by Campbell et al. in this issue of Liver Transplantation addresses this issue.16 They hypothesized that the duration of renal insufficiency, not the degree or the etiology, may be important in determining whether or not a patient would need a combined liver kidney transplant. Previously published series of patients had demonstrated that it was difficult to determine which patients would progress to ESRD following orthotopic liver transplantation based on pretransplantation creatinine or whether or not the patient required RRT prior to transplantation. However, Campbell et al. correctly point out that most of these reports and those reporting on the reversibility of HRS studied patients who underwent transplantation in the 1990s. Over the last few years more patients have been listed for transplantation, leading to an increase in waiting times. Therefore, Campbell et al. studied a cohort of patients with pre-existing renal dysfunction who underwent orthotopic liver transplantation from 2000 to 2003. They demonstrated that the duration of renal dysfunction, not the severity or etiology, predicts the 6-month and 12-month serum creatinine following orthotopic liver transplantation. Can this be reconciled with what has already been observed, and is it helpful in deciding on the need for combined transplantation? The answer to both questions is yes. There are patients who come to liver transplantation with a pre-existing renal dysfunction that is fixed and known, such as glomerulonephritis, diabetes mellitus, or hepatitis C in a longstanding dialysis patient. The decision to perform a combined transplantation in these patients is not controversial. If necessary, a kidney biopsy can be performed to gauge the severity of the disease. Population studies have demonstrated that glomerulosclerosis and arteriolar hyalinosis advances with age. In 60- to 69-year-old patients, the degree of glomerulosclerosis was found to be 7.8% in men and 3.8% in women.17 Furthermore, progression of underlying renal disease can be correlated with the degree of interstitial fibrosis (reviewed in Davis et al.18). Therefore, renal biopsy can help determine whether or not a patient may need a combined transplant. Suggested guidelines are that patients with more than 30% to 35% glomerulosclerosis or more than 25% to 30% interstitial fibrosis regardless of the underlying disease should be considered for combined liver kidney transplantation.9 This is not always feasible, so other parameters must be used. One can turn to the literature on acute renal failure for some guidance. When a patient develops acute renal failure, recovery usually occurs in the first 12 weeks. The longer the recovery, the more likely it is that the patient will have residual renal dysfunction that may persist and progress (reviewed in Davis et al.18). Can we apply this information to the patient with HRS? Previous studies of HRS have emphasized its reversibility after liver transplantation. However, most of these patients received transplants after short waiting periods, and even then 5% to 9% progressed to ESRD over time.7, 10 The end result of HRS is severe vasoconstriction of the renal vasculature. Before liver transplantation was available, patients died in a matter of days. If treated appropriately, patients receiving a liver transplant reversed the vasoconstriction rapidly and recovered. However, there are no studies that have examined the long-term effects of HRS on renal function when the patient has been supported with RRT for weeks. Does permanent damage occur because of ischemia to the kidneys? Is it reversible up to a certain time point? The report by Campbell et al.16 may shed some light on this. Their findings would suggest that after a period of prolonged HRS, the kidneys might not be able to fully recover. This gives the clinician one more parameter to use in evaluating the need for combined transplantation. They are correct in pointing out that in terms of length of dysfunction there is no absolute cutoff to use in selecting patients for combined transplantation. Some patients may recover even after prolonged periods of RRT. Their model for predicting 1-year serum creatinine was used on the patients who received combined transplants, and it predicted that all of those patients would have had a creatinine greater than 2 mg/dL at 1 year if they had received a liver transplant alone. This in itself would not justify transplantation. The series from Dallas demonstrated that patients who eventually progressed to ESRD had a mean creatinine of 2.5 mg/dL at 1 year postop.13 However, the median time to receive a kidney transplant in these patients after orthotopic liver transplantation was 51 months, and the median time to dialysis for those not receiving a transplant was 88 months. Given the long natural history of progression, a predicted creatinine of 2 mg/dL at 1 year should not be used alone to justify a combined transplantation. The authors of this article point out the correct way to approach this problem. Attempt careful assessment of the cause of renal dysfunction and obtain renal biopsy if practical; renal pathology is helpful in predicting recoverability. Appropriately treat patients to in an attempt to reverse the renal dysfunction; this will lower the risk for a patient undergoing liver transplantation alone. A recent study from Barcelona reported that HRS patients aggressively treated with vasopressin analogs before transplantation had outcomes identical to those in non-HRS patients.19 Patients determined to be neither end-stage nor at risk to progress rapidly to end-stage should be aggressively supported. If renal dysfunction and the need for RRT persist for more than 12 to 16 weeks, re-evaluate the patient. It is more likely that the patient may need combined liver transplantation. The observation reported in the paper by Campbell et al. along with previous studies on these difficult patients should serve as a stimulus for future studies of this important problem. Caution should still be used in selecting patients for the combined procedure to make certain that deceased donor kidneys are appropriately used. Indiscriminate or inappropriate utilization of this scarce resource may be detrimental to the ever-growing population of patients awaiting kidney transplantation. Until clear guidelines are established for selecting patients for combined transplantation, evaluation of these patients will require a careful and thorough approach and collaboration between the hepatologist, nephrologists, intensivist, and transplant surgeon caring for the patient.
No takes yet. Share an insight, caveat, or question.
Thomas A. Gonwa (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: